HRP20120976T1 - Derivati piridazinona - Google Patents
Derivati piridazinona Download PDFInfo
- Publication number
- HRP20120976T1 HRP20120976T1 HRP20120976AT HRP20120976T HRP20120976T1 HR P20120976 T1 HRP20120976 T1 HR P20120976T1 HR P20120976A T HRP20120976A T HR P20120976AT HR P20120976 T HRP20120976 T HR P20120976T HR P20120976 T1 HRP20120976 T1 HR P20120976T1
- Authority
- HR
- Croatia
- Prior art keywords
- denotes
- atoms
- nhet1
- stereoisomers
- tautomers
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- -1 pyrroldiyl Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000001634 furandiyl group Chemical group O1C(=C(C=C1)*)* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Claims (18)
1. Spojevi sa formulom I
[image]
naznačeni time da
D označava petero- ili šestero-člani nezasićeni ili aromatski heterocikal koji ima 1 do 3 N, O i/ili S atoma, koji mogu biti nesupstituirani ili mono-, di- ili trisupstituirani sa Hal i/ili A,
R1 označava Ar ili Het,
R2 označava nezasićeni ili aromatski petero- ili šestero-člani heterocikal koji ima 1 do 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili mono- ili disupstituirani sa Hal, A, OH, OA, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, Het1, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, O[C(R3)2]pN(R3)2, O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]pN(R3)2, NHCOO[C(R3)2]nHet1, NHCONH[C(R3)2]pN(R3)2, NHCONH[C(R3)2]nHet1, OCONH[C(R3)2]pN(R3)2, OCONH[C(R3)2]nHet1, CO-Het1, CHO, COA, =S, =NH, =NA i/ili =O (karbonil kisik),
R3 označava H ili A',
R4 označava H, A ili Hal,
A označava nerazgranati ili razgranati alkil koji ima 1-10 C atoma, u kojem 1-7 H atoma može biti zamijenjeno sa OH, F, Cl i/ili Br, i/ili u kojem jedna ili dvije CH2 skupine mogu biti zamijenjene sa O, NH, S, SO, SO2 i/ili CH=CH skupinama, ili ciklički alkil koji ima 3-7 C atoma, u kojem 1-7 H atoma može biti zamijenjeno sa OH, F, Cl i/ili Br,
A' označava nerazgranati ili razgranati alkil koji ima 1-6 C atoma, u kojem 1-5 H atoma može biti zamijenjeno sa F,
Ar označava fenil, naftil ili bifenil, svaki od kojih je nesupstituiran ili mono-, di- ili trisupstituiran sa Hal, A, OH, OA, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, CO-Het1, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, O[C(R3)2]pN(R3)2, O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]pN(R3)2, NHCOO[C(R3)2]nHet1, NHCONH[C(R3)2]pN(R3)2, NHCONH[C(R3)2]nHet1, OCONH[C(R3)2]pN(R3)2 i/ili OCONH[C(R3)2]nHet1,
Het označava mono-, bi- ili triciklički zasićeni, nezasićeni ili aromatski heterocikal koji ima 1 do 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili mono-, di- ili trisupstituirani sa Hal, A, OH, OA, N(R3)2, SR3, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, SO2N(R3)2, S(O)mA, Het1, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, O[C(R3)2]pN(R3)2, O[C(R3)2]nHet1, NHCOOA, NHCON(R3)2, NHCOO[C(R3)2]pN(R3)2, NHCOO[C(R3)2]nHet1, NHCONH[C(R3)2]pN(R3)2, NHCONH[C(R3)2]nHet1, OCONH[C(R3)2]pN(R3)2, OCONH[C(R3)2]nHet1, CO-Het1, CHO, COA, =S, =NH, =NA i/ili =O (karbonil kisik),
Het1 označava monociklički zasićeni heterocikal koji ima 1 do 2 N i/ili O atoma, koji mogu biti mono- ili disupstituirani sa A, OA, OH, Hal i/ili =O (karbonil kisik),
Hal označava F, Cl, Br ili I,
m označava 0, 1 ili 2,
n označava 0, 1, 2, 3 ili 4,
p označava 2, 3, 4, 5 ili 6,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
2. Spojevi prema zahtjevu 1 naznačeni time da
D označava tiazoldiil, tiofendiil, furandiil, piroldiil, oksazoldiil, izoksazoldiil, oksadiazoldiil, pirazoldiil, imidazoldiil, tiadiazoldiil, piridazindiil, pirazindiil, piridindiil ili pirimidindiil,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
3. Spojevi prema zahtjevu 1 ili 2 naznačeni time da
R2 označava pirazolil, piridinil, pirimidinil, furil, tienil, oksazolil, oksadiazolil, imidazolil, pirolil ili izoksazolil, svaki od kojih je monosupstituiran sa A ili [C(R3)2]nHet1,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
4. Spojevi prema jednom ili više zahtjeva od 1-3 naznačeni time da
R3 označava H ili metil,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
5. Spojevi prema jednom ili više zahtjeva od 1-4 naznačeni time da
R4 označava H,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
6. Spojevi prema jednom ili više zahtjeva od 1-5 naznačeni time da
Ar označava fenil koji je mono-, di- ili trisupstituiran sa Hal i/ili CN,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
7. Spojevi prema jednom ili više zahtjeva od 1-6 naznačeni time da
A označava nerazgranati ili razgranati alkil koji ima 1-6 C atoma, u kojem 1-5 H atoma može biti zamijenjeno sa F, i/ili u kojem jedna ili dvije CH2 skupine mogu biti zamijenjene sa O,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
8. Spojevi prema jednom ili više zahtjeva od 1-7 naznačeni time da
Het označava monociklički aromatski heterocikal koji ima 1 do 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili mono- ili disupstituirani sa A,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
9. Spojevi prema jednom ili više zahtjeva od 1-8 naznačeni time da
Het označava pirazolil, piridinil, pirimidinil, furil, tienil, oksazolil, oksadiazolil, imidazolil, pirolil ili izoksazolil, pri čemu radikali mogu također biti mono- ili disupstituirani sa A,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
10. Spojevi prema jednom ili više zahtjeva od 1-9 naznačeni time da
Het1 označava piperidinil, pirolidinil, morfolinil, piperazinil, oksazolidinil ili imidazolidinil, pri čemu radikali mogu također biti mono- ili disupstituirani sa =O i/ili A,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
11. Spojevi prema jednom ili više zahtjeva od 1-10 naznačeni time da
D označava tiazoldiil, tiofendiil, furandiil, piroldiil, oksazoldiil, izoksazoldiil, oksadiazoldiil, pirazoldiil, imidazoldiil, tiadiazoldiil, piridazindiil, pirazindiil, piridindiil ili pirimidindiil,
R1 označava Ar ili Het,
R2 označava pirazolil, piridinil, pirimidinil, furil, tienil, oksazolil, oksadiazolil, imidazolil, pirolil ili izoksazolil, svaki od kojih je monosupstituiran sa A ili [C(R3)2]nHet1,
R3 označava H ili metil,
R4 označava H,
A označava nerazgranati ili razgranati alkil koji ima 1-6 C atoma, u kojem 1-5 H atoma može biti zamijenjeno sa F, i/ili u kojem jedna ili dvije CH2 skupine mogu biti zamijenjene sa O,
Ar označava fenil koji je mono-, di- ili trisupstituiran sa Hal i/ili CN,
Het označava monociklički aromatski heterocikal koji ima 1 do 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili mono- ili disupstituirani sa A,
Het1 označava monociklički zasićeni heterocikal koji ima 1 do 2 N i/ili O atoma, koji mogu biti mono- ili disupstituirani sa A, OA, OH, Hal i/ili =O (karbonil kisik),
Hal označava F, Cl, Br ili I,
n označava 0, 1, 2, 3 ili 4,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
12. Spojevi prema jednom ili više zahtjeva od 1-11 naznačeni time da
D označava tiazoldiil, tiofendiil, furandiil, piroldiil, oksazoldiil, izoksazoldiil, oksadiazoldiil, pirazoldiil, imidazoldiil, tiadiazoldiil, piridazindiil, pirazindiil, piridindiil ili pirimidindiil,
R1 označava Ar ili Het,
R2 označava pirazolil, piridinil, pirimidinil, furil, tienil, oksazolil, oksadiazolil, imidazolil, pirolil ili izoksazolil, svaki od kojih je monosupstituiran sa A ili [C(R3)2]nHet1,
R3 označava H ili metil,
R4 označava H,
A označava nerazgranati ili razgranati alkil koji ima 1-6 C atoma, u kojem 1-5 H atoma može biti zamijenjeno sa F, i/ili u kojem jedna ili dvije CH2 skupine mogu biti zamijenjene sa O,
Ar označava fenil koji je mono-, di- ili trisupstituiran sa Hal i/ili CN,
Het označava pirazolil, piridinil, pirimidinil, furil, tienil, oksazolil, oksadiazolil, imidazolil, pirolil ili izoksazolil, pri čemu radikali mogu također biti mono- ili disupstituirani sa A,
Het1 označava piperidinil, pirolidinil, morfolinil, piperazinil, oksazolidinil ili imidazolidinil, pri čemu radikali mogu također biti mono- ili disupstituirani sa =O i/ili A,
Hal označava F, Cl, Br ili I,
n označava 0, 1, 2, 3 ili 4,
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
13. Spojevi prema zahtjevu 1, naznačeni time da su odabrani iz skupine:
[image]
i njihove farmaceutski korisne soli, tautomeri i stereoizomeri, uključujući njihove mješavine u svim omjerima.
14. Postupak za dobivanje spojeva sa formulom I prema zahtjevima 1-13 i njihovih farmaceutski korisnih soli, tautomera i stereoizomera, naznačen time da
a) spoj sa formulom II
[image]
u kojem R1 ima značenje navedeno u zahtjevu 1,
reagira sa spojem sa formulom III
[image]
u kojem D, R2, R3 i R4 imaju značenja navedena u zahtjevu 1 i
L označava Cl, Br, I ili slobodnu ili reaktivno funkcionalno izmijenjenu OH skupinu,
i/ili
baza ili kiselina formule I se pretvara u jednu od njezinih soli.
15. Lijekovi naznačeni time da sadrže barem jedan spoj sa formulom I prema zahtjevima 1-13 i/ili njihove farmaceutske korisne soli, tautomere i stereoizomere, uključujući njihove mješavine u svim omjerima, te proizvoljno pomoćne tvari i/ili adjuvante.
16. Uporaba spojeva prema zahtjevima 1-13 i njihovih farmaceutski korisnih soli, tautomera i stereoizomera, uključujući njihove mješavine u svim omjerima, naznačena time da je za dobivanje lijeka za liječenje bolesti, gdje je bolest koja se liječi solidni tumor ili tumor krvi i imunološkog sustava.
17. Lijekovi naznačeni time da sadrže barem jedan spoj sa formulom I prema jednom ili više zahtjeva od 1 do 13 i/ili njihove farmaceutski korisne soli, tautomere i stereoizomere, uključujući njihove mješavine u svim omjerima, te barem jedan dodatni aktivni ljekoviti spoj.
18. Komplet (kit) naznačen time da sadrži odvojena pakiranja
a) učinkovite količine spoja sa formulom I prema jednom ili više zahtjeva od 1 do 13, i/ili njihovih farmaceutski korisnih soli i stereoizomera, uključujući njihove mješavine u svim omjerima, te
b) učinkovite količine dodatnog aktivnog ljekovitog spoja.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009004061A DE102009004061A1 (de) | 2009-01-08 | 2009-01-08 | Pyridazinonderivate |
| PCT/EP2009/008839 WO2010078909A1 (de) | 2009-01-08 | 2009-12-10 | Pyridazinonderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120976T1 true HRP20120976T1 (hr) | 2012-12-31 |
Family
ID=41581157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120976AT HRP20120976T1 (hr) | 2009-01-08 | 2012-11-29 | Derivati piridazinona |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8623870B2 (hr) |
| EP (1) | EP2373647B1 (hr) |
| JP (1) | JP5683488B2 (hr) |
| KR (1) | KR101669696B1 (hr) |
| CN (1) | CN102272131A (hr) |
| AR (1) | AR074997A1 (hr) |
| AU (1) | AU2009336851B2 (hr) |
| BR (1) | BRPI0923903B8 (hr) |
| CA (1) | CA2749015C (hr) |
| CY (1) | CY1113700T1 (hr) |
| DE (1) | DE102009004061A1 (hr) |
| DK (1) | DK2373647T3 (hr) |
| EA (1) | EA020574B1 (hr) |
| ES (1) | ES2398023T3 (hr) |
| HR (1) | HRP20120976T1 (hr) |
| IL (1) | IL213826A (hr) |
| MX (1) | MX2011007209A (hr) |
| PL (1) | PL2373647T3 (hr) |
| PT (1) | PT2373647E (hr) |
| SG (1) | SG172458A1 (hr) |
| SI (1) | SI2373647T1 (hr) |
| SM (1) | SMT201300010B (hr) |
| WO (1) | WO2010078909A1 (hr) |
| ZA (1) | ZA201105781B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999025697A1 (fr) | 1997-11-19 | 1999-05-27 | Kowa Co., Ltd. | Nouveaux derives de pyridazine et medicaments contenant ces composes comme principe actif |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| EP1463509A1 (en) | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
| RU2004117082A (ru) | 2001-12-05 | 2005-04-10 | Орто-Макнейл Фармасьютикал, Инк. (Us) | Кетолидные 6-0-ацил-производные эритромицина в качестве антибактериальных средств |
| WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗ｈｃｖ作用を有する縮合ヘテロ環化合物 |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| EP1959955B1 (en) | 2005-12-05 | 2010-11-17 | Pfizer Products Inc. | Method of treating abnormal cell growth |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| DE102007061963A1 (de) * | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2010075068A1 (en) * | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
-
2009
- 2009-01-08 DE DE102009004061A patent/DE102009004061A1/de not_active Withdrawn
- 2009-12-10 US US13/143,646 patent/US8623870B2/en active Active
- 2009-12-10 CN CN2009801537887A patent/CN102272131A/zh active Pending
- 2009-12-10 JP JP2011544797A patent/JP5683488B2/ja active Active
- 2009-12-10 SI SI200930433T patent/SI2373647T1/sl unknown
- 2009-12-10 EP EP09768339A patent/EP2373647B1/de active Active
- 2009-12-10 DK DK09768339.5T patent/DK2373647T3/da active
- 2009-12-10 CA CA2749015A patent/CA2749015C/en active Active
- 2009-12-10 ES ES09768339T patent/ES2398023T3/es active Active
- 2009-12-10 PT PT97683395T patent/PT2373647E/pt unknown
- 2009-12-10 EA EA201101038A patent/EA020574B1/ru not_active IP Right Cessation
- 2009-12-10 SG SG2011048568A patent/SG172458A1/en unknown
- 2009-12-10 WO PCT/EP2009/008839 patent/WO2010078909A1/de active Application Filing
- 2009-12-10 PL PL09768339T patent/PL2373647T3/pl unknown
- 2009-12-10 BR BRPI0923903A patent/BRPI0923903B8/pt active IP Right Grant
- 2009-12-10 AU AU2009336851A patent/AU2009336851B2/en active Active
- 2009-12-10 KR KR1020117018119A patent/KR101669696B1/ko active IP Right Grant
- 2009-12-10 MX MX2011007209A patent/MX2011007209A/es active IP Right Grant
-
2010
- 2010-01-08 AR ARP100100034A patent/AR074997A1/es active IP Right Grant
-
2011
- 2011-06-28 IL IL213826A patent/IL213826A/en not_active IP Right Cessation
- 2011-08-05 ZA ZA2011/05781A patent/ZA201105781B/en unknown
-
2012
- 2012-11-29 HR HRP20120976AT patent/HRP20120976T1/hr unknown
- 2012-12-21 CY CY20121101250T patent/CY1113700T1/el unknown
-
2013
- 2013-01-18 SM SM201300010T patent/SMT201300010B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009336851B2 (en) | 2016-03-03 |
| AR074997A1 (es) | 2011-03-02 |
| EA020574B1 (ru) | 2014-12-30 |
| CN102272131A (zh) | 2011-12-07 |
| ES2398023T3 (es) | 2013-03-13 |
| SG172458A1 (en) | 2011-08-29 |
| US20110269771A1 (en) | 2011-11-03 |
| US8623870B2 (en) | 2014-01-07 |
| EA201101038A1 (ru) | 2012-01-30 |
| CA2749015C (en) | 2017-10-31 |
| DK2373647T3 (da) | 2012-12-10 |
| ZA201105781B (en) | 2012-04-25 |
| EP2373647A1 (de) | 2011-10-12 |
| CA2749015A1 (en) | 2010-07-15 |
| JP2012514612A (ja) | 2012-06-28 |
| IL213826A0 (en) | 2011-07-31 |
| BRPI0923903B1 (pt) | 2020-03-24 |
| AU2009336851A1 (en) | 2011-08-25 |
| SI2373647T1 (sl) | 2013-01-31 |
| PT2373647E (pt) | 2013-01-30 |
| JP5683488B2 (ja) | 2015-03-11 |
| PL2373647T3 (pl) | 2013-03-29 |
| KR20110099799A (ko) | 2011-09-08 |
| BRPI0923903A2 (pt) | 2015-07-28 |
| MX2011007209A (es) | 2011-08-04 |
| DE102009004061A1 (de) | 2010-07-15 |
| EP2373647B1 (de) | 2012-10-31 |
| KR101669696B1 (ko) | 2016-10-27 |
| SMT201300010B (it) | 2013-03-08 |
| BRPI0923903B8 (pt) | 2021-05-25 |
| IL213826A (en) | 2016-07-31 |
| CY1113700T1 (el) | 2016-06-22 |
| WO2010078909A1 (de) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120979T1 (hr) | Derivati piridazinona | |
| HRP20110441T1 (hr) | Derivati 2-benzilpiridazinona kao inhibitori met kinaze | |
| HRP20170100T1 (hr) | Derivati piridazinona | |
| HRP20161763T1 (hr) | Derivati dihidropirazolopirimidinona | |
| AU2016368317B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| JP2015529229A5 (hr) | ||
| JP7034162B2 (ja) | インフルエンザウイルス複製の阻害剤及びその使用 | |
| HRP20120346T1 (hr) | Derivati kinolinona kao parp i tank inhibitori | |
| HRP20150030T1 (hr) | Derivati pirazolokinolina kao inhibitori dna-pk | |
| HRP20170499T1 (hr) | Derivati tiazola | |
| RU2008109908A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| BRPI0717767A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase | |
| HRP20150139T1 (hr) | Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina | |
| HRP20201944T1 (hr) | Inhibitori kinaze povezane sa tropomiozinom (trk) | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| JP2008530240A5 (hr) | ||
| RU2015115278A (ru) | Производные гидропирролопиррола для применения в качестве ингибиторов синтазы жирных кислот | |
| JP2014518884A5 (hr) | ||
| HRP20120510T1 (hr) | Derivati beta amino kiseline za liječenje dijabetesa | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| HRP20211801T1 (hr) | Derivati kinolin-2-ona | |
| HRP20160495T1 (hr) | Morfolinilbenzotriazini za uporabu u terapiji raka | |
| JP2013523814A5 (hr) | ||
| SI3087076T1 (en) | IMIDAZOPIRAZINONE DERIVATIVES | |
| AU2020368392A1 (en) | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |